The Relationship between Primary Gross Tumor Volume and Tumor Response of Locally Advanced Rectal Cancer: pGTV as a More Accurate Tumor Size Indicator

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Torok JA, Palta M, Willett CG, Czito BG. Nonoperative management of rectal cancer. Cancer 2016;122(1):34–41. doi:10.1002/cncr.29735.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20(2):207–239. doi:10.1007/s10147-015-0801-z.
   PubMed Web of Science ®Google Scholar
• Monson JR, Weiser MR, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum. 2013;56(5):535–550. doi:10.1097/DCR.0b013e31828cb66c.
   PubMed Web of Science ®Google Scholar
• Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–1933. doi:10.1200/JCO.2011.40.1836.
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–1740. doi:10.1056/NEJMoa040694.
   PubMed Web of Science ®Google Scholar
• Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30(15):1770–1776. doi:10.1200/JCO.2011.39.7901.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Lu J, Zhong G, et al. [Downstaging correlates the prognosis of rectal cancer after intensified neoadjuvant chemoradiotherapy]. Zhonghua Wei Chang Wai Ke Za Zhi 2014;17:547–550.
   PubMedGoogle Scholar
• Nahas SC, Nahas CSR, Cama GM, et al. Diagnostic performance of magnetic resonance to assess treatment response after neoadjuvant therapy in patients with locally advanced rectal cancer. Abdom Radiol (NY) 2019;1–9. Available from: https://doi.org/10.1007/s00261-019-01894-8
   PubMed Web of Science ®Google Scholar
• Giannini V, Mazzetti S, Bertotto I, et al. Predicting locally advanced rectal cancer response to neoadjuvant therapy with (18)F-FDG PET and MRI radiomics features. Eur J Nucl Med Mol Imaging 2019; 46(4):878–888.
   PubMed Web of Science ®Google Scholar
• Wei J, Huang R, Guo S, et al. ypTNM category combined with AJCC tumor regression grade for screening patients with the worst prognosis after neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Cmar. 2018;10:5219–5225. doi:10.2147/CMAR.S179151.
   Google Scholar
• Petrillo A, Fusco R, Granata V, et al. Assessing response to neo-adjuvant therapy in locally advanced rectal cancer using intra-voxel incoherent motion modelling by DWI data and Standardized Index of Shape from DCE-MRI. Ther Adv Med Oncol. 2018;10:175883591880987. doi:10.1177/1758835918809875.
   Web of Science ®Google Scholar
• De Felice F, Izzo L, Musio D, et al. Clinical predictive factors of pathologic complete response in locally advanced rectal cancer. Oncotarget 2016;7:33374–33380.
   PubMedGoogle Scholar
• Garland ML, Vather R, Bunkley N, Pearse M, Bissett IP. Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Int J Colorectal Dis. 2014;29(3):301–307. doi:10.1007/s00384-013-1821-7.
   PubMed Web of Science ®Google Scholar
• Sorensen AG, Patel S, Harmath C, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol. 2001;19(2):551–557. doi:10.1200/JCO.2001.19.2.551.
   PubMed Web of Science ®Google Scholar
• Studer G, Lutolf UM, El-Bassiouni M, Rousson V, Glanzmann C. Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT. Acta Oncol. 2007;46(3):386–394. doi:10.1080/02841860600815407.
   PubMed Web of Science ®Google Scholar
• Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2012;19(7):2212–2223. doi:10.1245/s10434-011-2210-5.
   PubMed Web of Science ®Google Scholar
• Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–8696. doi:10.1200/JCO.2005.02.1329.
   PubMed Web of Science ®Google Scholar
• Park JW, Lim SB, Kim DY, et al. Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. Int J Radiat Oncol Biol Phys. 2009;74(3):810–817. doi:10.1016/j.ijrobp.2008.08.057.
   PubMed Web of Science ®Google Scholar
• Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73(11):2680–2686.
   PubMed Web of Science ®Google Scholar
• Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98(7):1521–1530. doi:10.1002/cncr.11660.
   PubMed Web of Science ®Google Scholar
• Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229(3):303–308.
   PubMed Web of Science ®Google Scholar
• Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061–3071. doi:10.1200/JCO.2002.11.027.
   PubMed Web of Science ®Google Scholar
• Braun OM, Neumeister B, Popp W, et al. Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy. Cancer 1989;63(6):1097–1100.
   PubMed Web of Science ®Google Scholar
• Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32(15):1554–1562. doi:10.1200/JCO.2013.54.3769.
   PubMed Web of Science ®Google Scholar
• Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62(3):752–760. doi:10.1016/j.ijrobp.2004.11.017.
   PubMed Web of Science ®Google Scholar
• Bitterman DS, Resende Salgado L, Moore HG, et al. Predictors of complete response and disease recurrence following chemoradiation for rectal cancer. Front Oncol. 2015;5:286.
   PubMed Web of Science ®Google Scholar
• Probst CP, Becerra AZ, Aquina CT, et al. Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumor response and potential organ preservation. J Am Coll Surg. 2015;221(2):430–440. doi:10.1016/j.jamcollsurg.2015.04.010.
   PubMed Web of Science ®Google Scholar
• Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics 2013;33(5):1323–1341. doi:10.1148/rg.335125214.
   PubMed Web of Science ®Google Scholar
• Studer G, Rordorf T, Glanzmann C. Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer. Radiat Oncol. 2011;6:120.
   PubMed Web of Science ®Google Scholar
• Strongin A, Yovino S, Taylor R, et al. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(5):1823–1830. doi:10.1016/j.ijrobp.2010.10.053.
   PubMed Web of Science ®Google Scholar
• Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y, Nakaji S. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys. 2006;64(2):449–454. doi:10.1016/j.ijrobp.2005.07.967.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002;52(1):49–57. doi:10.1016/S0360-3016(01)01772-2.
   PubMed Web of Science ®Google Scholar
• Dubben HH, Thames HD, Beck-Bornholdt HP. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol. 1998;47(2):167–174. doi:10.1016/S0167-8140(97)00215-6.
   PubMed Web of Science ®Google Scholar
• Knegjens JL, Hauptmann M, Pameijer FA, et al. Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head Neck. 2011;33(3):375–382. doi:10.1002/hed.21459.
   PubMed Web of Science ®Google Scholar
• Perez RO. Complete clinical response in rectal cancer: a turning tide. Lancet Oncol. 2016;17(2):125–126. doi:10.1016/S1470-2045(15)00487-8.
   PubMed Web of Science ®Google Scholar
• Restivo A, Zorcolo L, Cocco IM, et al. Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer. Ann Surg Oncol. 2013;20(3):864–871. : doi:10.1245/s10434-012-2669-8.
   PubMed Web of Science ®Google Scholar
• Rodel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:979–989. doi:10.1016/S1470-2045(15)00159-X.
   PubMed Web of Science ®Google Scholar